Newsroom | 49435 results

カリフォルニア州サンカルロス--(BUSINESS WIRE)--（ビジネスワイヤ） -- グローバルなオンコロジー企業であるBeOne Medicines Ltd.（NASDAQ：ONC、HKEX：06160、SSE：688235）は、サンフランシスコで開催される第44 回「JPモルガン・ヘルスケア・カンファレンス」におけるプレゼンテーションで、拡大を続ける同社のオンコロジー領域のグローバルなリーダーシップを支える柱を示します。 BeOneの共同創業者で取締役会会長兼最高経営責任者（CEO）であるジョン・V・オイラーは、B細胞性悪性腫瘍の治療における同社の変革的なリーダーシップを強調します。本プレゼンテーションでは、ブルトン型チロシンキナーゼ（BTK）阻害薬の中で世界的に最も有力なBRUKINSA®に加え、血液がん領域の基盤となる資産として、次世代でベストインクラスとなる可能性を有するB細胞リンパ腫2（BCL2）阻害薬ソンロトクラックス（12月30日に初のグローバル規制当局承認を取得済）およびファーストインクラスかつベストインクラスとなる可能性を有するBTKを標的とするキメラ分解活...

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar’s Nasal Vaccine Delivery Solutions Featured in CastleVax Phase II Clinical Trial of an Intranasal COVID-19 Vaccine Candidate...

SAN FRANCISCO--(BUSINESS WIRE)--On the occasion of the 44th J.P. Morgan Healthcare Conference in San Francisco, Bayer AG today unveiled the strategic focus for its Pharmaceuticals Division in 2026. Capitalizing on new launch momentum, the company will drive significant global regulatory expansions and market penetration across its pharmaceutical portfolio. High-value commercial products and an accelerating modality-rich pipeline across oncology, cardiology, neurology, and immunology have firmly...

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc., (Nasdaq: TVTX) announced that today the U.S. Food and Drug Administration (FDA) has extended the review timeline of its supplemental New Drug Application (sNDA) for FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (FSGS). The new Prescription Drug User Fee Act (PDUFA) target action date is April 13, 2026. The extension follows the recent submission of responses requested by the FDA to further characterize the clinical benefit o...

PALO ALTO, Calif.--(BUSINESS WIRE)--Period of transformative growth across all major healthcare verticals follows its Series C, which raised $126 million at a $3.5 billion valuation....

SAN FRANCISCO--(BUSINESS WIRE)--Animate Bio reports positive preclinical data showing two AI-designed peptides reduced lung fibrosis & inflammation, with the lead matching nintedanib...

SAN CARLOS, Califórnia--(BUSINESS WIRE)--A BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), empresa global de oncologia, apresentará hoje os pilares de sua crescente liderança global em oncologia durante sua apresentação na 44ª Conferência Anual de Saúde do J.P. Morgan, em San Francisco. John V. Oyler, cofundador, presidente do conselho e CEO da BeOne, destacará a liderança transformadora da empresa no tratamento das malignidades de células B. A apresentação trará o BRUKINSA®, líde...

SAN CARLOS, California--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), una empresa global de oncología, presentará hoy los ejes de su creciente posicionamiento internacional durante su participación en la 44.a Conferencia Anual de Salud de J.P. Morgan, que se celebra en San Francisco. John V. Oyler, cofundador, presidente y director ejecutivo de BeOne, destacará el impacto transformador de la empresa en el tratamiento de malignidades de células B. La presentación...

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), società oncologica globale, evidenzierà i pilastri della sua crescente leadership oncologica globale durante la sua presentazione oggi alla 44a Annual Healthcare Conference di J.P. Morgan a San Francisco. John V. Oyler, Cofondatore, Presidente e CEO di BeOne, evidenzierà la leadership innovativa della Società nella terapia dei tumori maligni a cellule B. La presentazione includerà BRUKINSA®, l'ini...

SAN CARLOS, Kalifornien--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), ein weltweit tätiges Onkologieunternehmen, wird im Rahmen seiner heutigen Präsentation auf der 44. jährlichen J.P. Morgan Healthcare Conference in San Francisco die Grundpfeiler seiner zunehmenden globalen Führungsrolle auf dem Gebiet der Onkologie vorstellen. John V. Oyler, Mitbegründer, Chairman und CEO von BeOne, wird die transformative Vorreiterrolle des Unternehmens bei der Behandlung vo...